Effects of Emicizumab on APTT, FVIII assays and FVIII Inhibitor assays using completely totally different reagents: Results of a UK NEQAS proficiency testing prepare Introduction: Emicizumab (Hemlibra: Roche Switzerland) is a, humanized, bi-specific monoclonal modified immunoglobulin G4 (IgG4) which binds human FX, FIX and activated FIX (FIXa) to mimic activated FVIII train. Aim: Evaluate the results… Continue reading
